MCID: WLM018
MIFTS: 60

Wilms Tumor 5

Categories: Genetic diseases, Nephrological diseases, Rare diseases, Cancer diseases, Fetal diseases

Aliases & Classifications for Wilms Tumor 5

MalaCards integrated aliases for Wilms Tumor 5:

Name: Wilms Tumor 5 57
Wilms Tumor 38 13 55 6 43 40
Wilms Tumor Susceptibility-5 57 13
Wt5 57 75
Hereditary Susceptibility to Wilms Tumor 5 75
Wilms Tumor and Radial Bilateral Aplasia 73
Wilms Tumor, Susceptibility to 57
Wilms Tumor, Type 5 40
Wilms Tumor ; Wtsl 57
Nephroblastoma 73
Wtsl 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
tumor suppressor gene
most cases are sporadic


HPO:

32

Classifications:



External Ids:

OMIM 57 601583
MedGen 42 C1832099
UMLS 73 C1832099

Summaries for Wilms Tumor 5

MedlinePlus : 43 Wilms tumor is a rare type of kidney cancer. It causes a tumor on one or both kidneys. It usually affects children, but can happen in adults. Having certain genetic conditions or birth defects can increase the risk of getting it. Children that are at risk should be screened for Wilms tumor every three months until they turn eight. Symptoms include a lump in the abdomen, blood in the urine, and a fever for no reason. Tests that examine the kidney and blood are used to find the tumor. Doctors usually diagnose and remove the tumor in surgery. Other treatments include chemotherapy and radiation and biologic therapies. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Wilms Tumor 5, also known as wilms tumor, is related to wilms tumor 1 and wilms tumor and radial bilateral aplasia, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 5 is POU6F2 (POU Class 6 Homeobox 2), and among its related pathways/superpathways are Proteoglycans in cancer and Wnt / Hedgehog / Notch. The drugs Itraconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include myeloid, kidney and bone, and related phenotypes are nephroblastoma and cardiovascular system

UniProtKB/Swiss-Prot : 75 Hereditary susceptibility to Wilms tumor 5: Pediatric malignancy of kidney and one of the most common solid cancers in childhood.

Description from OMIM: 601583

Related Diseases for Wilms Tumor 5

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 38)
# Related Disease Score Top Affiliating Genes
1 wilms tumor 1 30.4 CTNNB1 GPC3 H19 IGF2 PAX2 POU6F2
2 wilms tumor and radial bilateral aplasia 11.1
3 silver-russell syndrome due to an imprinting defect of 11p15 10.8 H19 IGF2
4 silver-russell syndrome due to 11p15 microduplication 10.8 H19 IGF2
5 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.8 H19 IGF2
6 silver-russell syndrome due to a point mutation 10.7 CDKN1C IGF2
7 wilson-turner x-linked mental retardation syndrome 10.6 IGF2 POU6F2 WT1
8 female reproductive endometrioid cancer 10.5 CTNNB1 WT1
9 renal adenoma 10.5 PAX2 WT1
10 nephrogenic adenoma of urinary bladder 10.5 PAX2 PAX8
11 rete testis adenoma 10.5 PAX2 PAX8
12 iris disease 10.4 IGF2 PAX6 WT1
13 scleral staphyloma 10.4 PAX2 PAX6
14 childhood endodermal sinus tumor 10.4 PAX2 PAX8
15 endosalpingiosis 10.4 PAX8 WT1
16 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 10.4 IGF2 PAX6 WT1
17 umbilical hernia 10.4 CDKN1C H19 IGF2
18 aniridia 1 10.4 IGF2 PAX6 WT1
19 simpson-golabi-behmel syndrome 10.4 CTNNB1 GPC3 IGF2
20 bladder benign neoplasm 10.3 IGF2 PAX2 PAX8
21 nephrogenic adenofibroma 10.3 PAX2 PAX8 WT1
22 pseudopapilledema 10.3 IGF2 PAX6
23 ovarian brenner tumor 10.3 PAX2 PAX8 WT1
24 silver-russell syndrome 10.2 CDKN1C H19 IGF2
25 hemihyperplasia, isolated 10.2 CDKN1C H19 IGF2 WT1
26 adrenocortical carcinoma, hereditary 10.2 CDKN1C CTNNB1 H19 IGF2
27 gastrointestinal system cancer 10.2 CTNNB1 GPC3 H19 IGF2
28 hereditary wilms' tumor 10.1 CDKN1C IGF2 PAX6 WT1
29 rhabdomyosarcoma 10.1 CYR61 H19 IGF2 NOV
30 nephrogenic adenoma 10.0 PAX2 PAX8
31 hepatic adenomas, familial 9.9 CTNNB1 GPC3
32 arthropathy, progressive pseudorheumatoid, of childhood 9.9 CTGF CYR61 WISP3
33 pauci-immune glomerulonephritis 9.9 CTGF SYNPO
34 renal cell carcinoma, nonpapillary 9.8 H19 PAX2 PAX8 WT1
35 hepatoblastoma 9.8 CDKN1C CTNNB1 GPC3 H19 IGF2
36 beckwith-wiedemann syndrome 9.8 CDKN1C GPC3 H19 IGF2 WT1
37 wilms tumor 6 9.7
38 focal segmental glomerulosclerosis 9.6 CDKN1C PAX2 SYNPO WT1

Graphical network of the top 20 diseases related to Wilms Tumor 5:



Diseases related to Wilms Tumor 5

Symptoms & Phenotypes for Wilms Tumor 5

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Kidneys:
nephroblastoma (wilms tumor)

Neoplasia:
nephroblastoma (wilms tumor)


Clinical features from OMIM:

601583

Human phenotypes related to Wilms Tumor 5:

32
# Description HPO Frequency HPO Source Accession
1 nephroblastoma 32 HP:0002667

UMLS symptoms related to Wilms Tumor 5:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 5:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.13 CTGF CTNNB1 CYR61 GPC3 IGF2 NOV
2 embryo MP:0005380 10.11 CTGF CTNNB1 CYR61 FZD6 GPC3 IGF2
3 mortality/aging MP:0010768 9.97 CTGF CTNNB1 CYR61 FZD6 GPC3 IGF2
4 craniofacial MP:0005382 9.95 PAX8 PAX6 CTGF CTNNB1 GPC3 IGF2
5 hearing/vestibular/ear MP:0005377 9.8 CTGF CTNNB1 FZD6 PAX2 PAX6 PAX8
6 limbs/digits/tail MP:0005371 9.8 CTGF CTNNB1 FZD6 GPC3 IGF2 NOV
7 renal/urinary system MP:0005367 9.61 CTNNB1 GPC3 IGF2 NOV PAX2 PAX6
8 vision/eye MP:0005391 9.23 CTGF CTNNB1 FZD6 IGF2 NOV PAX2

Drugs & Therapeutics for Wilms Tumor 5

Drugs for Wilms Tumor 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
4 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
6 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10
Hydroxyitraconazole Phase 4,Phase 3,Not Applicable
11 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
12
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
13
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
14
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
15
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
16
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
17
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
18
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
19
Decitabine Approved, Investigational Phase 2, Phase 3,Phase 1 2353-33-5 451668
20
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
21
Morphine Approved, Investigational Phase 3 57-27-2 5288826
22
Cytarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 147-94-4 6253
23
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
24
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
25
Sulfamethoxazole Approved Phase 3 723-46-6 5329
26
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
27
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1 21679-14-1, 75607-67-9 30751
28
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
29
Mycophenolic acid Approved Phase 3 24280-93-1 446541
30
Captopril Approved Phase 3 62571-86-2 44093
31
Palivizumab Approved, Investigational Phase 3 188039-54-5
32
Ribavirin Approved Phase 3 36791-04-5 37542
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
35
Caspofungin Approved Phase 3,Not Applicable 179463-17-3, 162808-62-0 468682 2826718
36
Acyclovir Approved Phase 3 59277-89-3 2022
37
Histamine Approved, Investigational Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
38
Cyproheptadine Approved Phase 3 129-03-3 2913
39
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
40
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
41 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
43 Antimitotic Agents Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
46 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Etoposide phosphate Phase 3,Phase 2,Phase 1
50 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
2 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
3 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
4 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
5 Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
6 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
7 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
8 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Completed NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
9 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
10 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
11 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
12 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
13 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3 FLAIMy - Fluda, Ida, Ara-C, Mylotarg
14 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3 gemtuzumab ozogamycin
15 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
16 HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk Completed NCT02461121 Phase 3 cyclosporine A;Mycophenolate mofetil;Ara-C;fludarabine;anti-lymphocyte globulin;cyclophosphamide
17 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
18 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
19 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
20 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
21 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
22 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
23 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
24 A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Completed NCT00927498 Phase 3 conventional chemotherapy (AraC + Daunorubicin),;Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
25 Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 Recruiting NCT02473146 Phase 2, Phase 3 Gemtuzumab ozogamicin (GO)
26 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
27 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
28 Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Unknown status NCT01513109 Phase 1, Phase 2
29 WT1 Peptid Vaccination in Carcinomas Unknown status NCT00153608 Phase 2
30 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
31 WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Unknown status NCT00153582 Phase 2
32 Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma Unknown status NCT00965224 Phase 2
33 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
34 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
35 Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer Unknown status NCT02018458 Phase 1, Phase 2
36 Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Unknown status NCT01956630 Phase 1, Phase 2
37 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
38 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
39 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
40 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
41 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
42 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen
43 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
44 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
45 Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Completed NCT00488592 Phase 2 GM-CSF (Sargramostim)
46 Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy Completed NCT01819558 Phase 1, Phase 2
47 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
48 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Completed NCT00405327 Phase 2
49 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
50 Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD Completed NCT02027805 Phase 1, Phase 2

Search NIH Clinical Center for Wilms Tumor 5

Genetic Tests for Wilms Tumor 5

Anatomical Context for Wilms Tumor 5

MalaCards organs/tissues related to Wilms Tumor 5:

41
Myeloid, Kidney, Bone, T Cells, Bone Marrow, Testes, Lung

Publications for Wilms Tumor 5

Articles related to Wilms Tumor 5:

(show top 50) (show all 1513)
# Title Authors Year
1
Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells. ( 29589053 )
2018
2
Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. ( 29482572 )
2018
3
Immunoreactivity of Wilms tumor 1 (WT1) as an additional evidence supporting hemangiomatous rather than inflammatory origin in the etiopathogenesis of angiolymphoid hyperplasia with eosinophilia. ( 29445571 )
2018
4
Wilms' Tumor 1 Overexpression in Granulosa Cells Is Associated with Polycystic Ovaries in Polycystic Ovary Syndrome Patients. ( 29414825 )
2018
5
Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction. ( 28994041 )
2018
6
Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay. ( 28573960 )
2018
7
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
8
Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. ( 29933069 )
2018
9
Simultaneous Presentation of Wilms' Tumor and Contralateral Ganglioneuroma in a Child: Case Report and Literature Review. ( 29334535 )
2018
10
Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation. ( 29753838 )
2018
11
Description of mutation spectrum and polymorphism of Wilms' tumor 1 (WT1) gene in hypospadias patients in the Indonesian population. ( 29958641 )
2018
12
Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor. ( 29932284 )
2018
13
Urine cell-free DNA is a biomarker for nephroblastomatosis or Wilms tumor in PIK3CA-related overgrowth spectrum (PROS). ( 29300373 )
2018
14
Clinicopathological parameters and prognostic relevance of miR-21 and PTEN expression in Wilms' tumor. ( 28040201 )
2017
15
Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein. ( 28299466 )
2017
16
Inhibitory effect of Par-4 combined with cisplatin on human Wilms' tumor cells. ( 28720068 )
2017
17
Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. ( 28553959 )
2017
18
Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. ( 28067876 )
2017
19
Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. ( 28188683 )
2017
20
Glypican-3 mRNA expression level in Wilms tumor: correlation with histological type, stage, and outcome. ( 28432433 )
2017
21
Wilms Tumor Treatment Outcomes: Perspectives From a Low-Income Setting. ( 29094095 )
2017
22
Encephalocraniocutaneous lipomatosis with Wilms' tumor. ( 28612492 )
2017
23
The Wilms tumor protein Wt1 contributes to female fertility by regulating oviductal proteostasis. ( 28334862 )
2017
24
Over-Expression of miR-21 and Lower PTEN Levels in Wilms' Tumor with Aggressive Behavior. ( 28529243 )
2017
25
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. ( 29100432 )
2017
26
Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway. ( 28322459 )
2017
27
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis. ( 28054314 )
2017
28
Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. ( 28950074 )
2017
29
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. ( 28369773 )
2017
30
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. ( 27866185 )
2017
31
Simultaneous Presentation of Wilms Tumor and Immature Ovarian Teratoma in Beckwith-Wiedemann Syndrome. ( 28692553 )
2017
32
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification. ( 27922671 )
2017
33
Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. ( 28674120 )
2017
34
Association Between HACE1 Gene Polymorphisms and Wilms' Tumor Risk in a Chinese Population. ( 29243987 )
2017
35
Sonographic screening for Wilms tumor in children with CLOVES syndrome. ( 28627003 )
2017
36
Nucleotide Transition 390C-T in the Wilms' Tumor 1 Gene: A Risk Factor of Hypospadias? ( 28878596 )
2017
37
Osteopathia striata with cranial sclerosis and Wilms tumor: Coincidence or consequence? ( 29120061 )
2017
38
Transcription factor Wilms' tumor 1 regulates developmental RNAs through 3' UTR interaction. ( 28289143 )
2017
39
Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia. ( 28567073 )
2017
40
Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients. ( 28163010 )
2017
41
Pencil beam scanning proton therapy for treatment of the retroperitoneum after nephrectomy for Wilms tumor: A dosimetric comparison study. ( 27565764 )
2017
42
Truncating Wilms Tumor Suppressor Gene 1 Mutation in an XX Female with Adult-Onset Focal Segmental Glomerulosclerosis and Streak Ovaries: A Case Report. ( 27701157 )
2017
43
Molecular cloning of canine Wilms' tumor 1 for immunohistochemical analysis in canine tissues. ( 28603218 )
2017
44
Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. ( 28107196 )
2017
45
Association between<i>TP53</i>gene Arg72Pro polymorphism and Wilms' tumor risk in a Chinese population. ( 28260929 )
2017
46
Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation. ( 28673850 )
2017
47
Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells. ( 27889611 )
2017
48
Palliative radiation therapy for superior vena cava syndrome in metastatic Wilms tumor using 10XFFF and 3D surface imaging to avoid anesthesia in a pediatric patient-a teaching case. ( 28740919 )
2017
49
Activation of the Wnt/I^-catenin pathway is common in wilms tumor, but rarely through I^-catenin mutation and APC promoter methylation. ( 27679509 )
2016
50
Is Nephron Sparing Surgery Justified in Wilms Tumor With Beckwith-Wiedemann Syndrome or Isolated Hemihypertrophy? ( 27228957 )
2016

Variations for Wilms Tumor 5

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 5:

75
# Symbol AA change Variation ID SNP ID
1 POU6F2 p.Gln192His VAR_022419

ClinVar genetic disease variations for Wilms Tumor 5:

6
(show top 50) (show all 189)
# Gene Variation Type Significance SNP ID Assembly Location
1 POU6F2 NM_007252.3(POU6F2): c.573G> T (p.Gln191His) single nucleotide variant Pathogenic rs121918261 GRCh37 Chromosome 7, 39379302: 39379302
2 POU6F2 NM_007252.3(POU6F2): c.573G> T (p.Gln191His) single nucleotide variant Pathogenic rs121918261 GRCh38 Chromosome 7, 39339703: 39339703
3 POU6F2 POU6F2, C-G, EXON 1C, 5-PRIME UTR single nucleotide variant Pathogenic
4 CTNNB1 NM_001904.3(CTNNB1): c.133_135delTCT (p.Ser45del) deletion Pathogenic rs587776850 GRCh38 Chromosome 3, 41224645: 41224647
5 CTNNB1 NM_001904.3(CTNNB1): c.133_135delTCT (p.Ser45del) deletion Pathogenic rs587776850 GRCh37 Chromosome 3, 41266136: 41266138
6 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
7 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh38 Chromosome 3, 41224646: 41224646
8 WT1 NM_024426.4(WT1): c.108G> C (p.Pro36=) single nucleotide variant Conflicting interpretations of pathogenicity rs555140661 GRCh37 Chromosome 11, 32456784: 32456784
9 WT1 NM_024426.4(WT1): c.108G> C (p.Pro36=) single nucleotide variant Conflicting interpretations of pathogenicity rs555140661 GRCh38 Chromosome 11, 32435238: 32435238
10 WT1 NM_024426.4(WT1): c.330C> T (p.Pro110=) single nucleotide variant Benign rs1799925 GRCh37 Chromosome 11, 32456562: 32456562
11 WT1 NM_024426.4(WT1): c.330C> T (p.Pro110=) single nucleotide variant Benign rs1799925 GRCh38 Chromosome 11, 32435016: 32435016
12 WT1 NM_024426.4(WT1): c.1107A> G (p.Arg369=) single nucleotide variant Benign rs16754 GRCh37 Chromosome 11, 32417945: 32417945
13 WT1 NM_024426.4(WT1): c.1107A> G (p.Arg369=) single nucleotide variant Benign rs16754 GRCh38 Chromosome 11, 32396399: 32396399
14 WT1 NM_024426.4(WT1): c.1099-9T> C single nucleotide variant Benign/Likely benign rs5030274 GRCh38 Chromosome 11, 32396416: 32396416
15 WT1 NM_024426.4(WT1): c.1099-9T> C single nucleotide variant Benign/Likely benign rs5030274 GRCh37 Chromosome 11, 32417962: 32417962
16 WT1 NM_024426.4(WT1): c.360C> T (p.Gly120=) single nucleotide variant Conflicting interpretations of pathogenicity rs776209354 GRCh38 Chromosome 11, 32434986: 32434986
17 WT1 NM_024426.4(WT1): c.360C> T (p.Gly120=) single nucleotide variant Conflicting interpretations of pathogenicity rs776209354 GRCh37 Chromosome 11, 32456532: 32456532
18 WT1 NM_024426.4(WT1): c.294C> A (p.Gly98=) single nucleotide variant Benign/Likely benign rs547333427 GRCh38 Chromosome 11, 32435052: 32435052
19 WT1 NM_024426.4(WT1): c.294C> A (p.Gly98=) single nucleotide variant Benign/Likely benign rs547333427 GRCh37 Chromosome 11, 32456598: 32456598
20 WT1 NM_024426.4(WT1): c.201G> T (p.Gln67His) single nucleotide variant Benign/Likely benign rs5030135 GRCh38 Chromosome 11, 32435145: 32435145
21 WT1 NM_024426.4(WT1): c.201G> T (p.Gln67His) single nucleotide variant Benign/Likely benign rs5030135 GRCh37 Chromosome 11, 32456691: 32456691
22 WT1 NM_024426.4(WT1): c.166C> A (p.Arg56=) single nucleotide variant Benign/Likely benign rs2234581 GRCh38 Chromosome 11, 32435180: 32435180
23 WT1 NM_024426.4(WT1): c.166C> A (p.Arg56=) single nucleotide variant Benign/Likely benign rs2234581 GRCh37 Chromosome 11, 32456726: 32456726
24 WT1 NM_024426.4(WT1): c.68G> A (p.Gly23Glu) single nucleotide variant Uncertain significance rs751641518 GRCh38 Chromosome 11, 32435278: 32435278
25 WT1 NM_024426.4(WT1): c.68G> A (p.Gly23Glu) single nucleotide variant Uncertain significance rs751641518 GRCh37 Chromosome 11, 32456824: 32456824
26 WT1 NM_024426.4(WT1): c.1059A> G (p.Gln353=) single nucleotide variant Benign/Likely benign rs2234590 GRCh37 Chromosome 11, 32421533: 32421533
27 WT1 NM_024426.4(WT1): c.1059A> G (p.Gln353=) single nucleotide variant Benign/Likely benign rs2234590 GRCh38 Chromosome 11, 32399987: 32399987
28 WT1 NM_024426.4(WT1): c.681C> T (p.Ser227=) single nucleotide variant Benign/Likely benign rs9332974 GRCh38 Chromosome 11, 32428585: 32428585
29 WT1 NM_024426.4(WT1): c.681C> T (p.Ser227=) single nucleotide variant Benign/Likely benign rs9332974 GRCh37 Chromosome 11, 32450131: 32450131
30 WT1 NM_024426.4(WT1): c.594C> T (p.Asn198=) single nucleotide variant Benign/Likely benign rs2234583 GRCh37 Chromosome 11, 32456298: 32456298
31 WT1 NM_024426.4(WT1): c.594C> T (p.Asn198=) single nucleotide variant Benign/Likely benign rs2234583 GRCh38 Chromosome 11, 32434752: 32434752
32 WT1 NM_024426.4(WT1): c.498C> A (p.Gly166=) single nucleotide variant Benign/Likely benign rs536728682 GRCh38 Chromosome 11, 32434848: 32434848
33 WT1 NM_024426.4(WT1): c.498C> A (p.Gly166=) single nucleotide variant Benign/Likely benign rs536728682 GRCh37 Chromosome 11, 32456394: 32456394
34 WT1 NM_024426.4(WT1): c.366C> G (p.Pro122=) single nucleotide variant Conflicting interpretations of pathogenicity rs771681406 GRCh38 Chromosome 11, 32434980: 32434980
35 WT1 NM_024426.4(WT1): c.366C> G (p.Pro122=) single nucleotide variant Conflicting interpretations of pathogenicity rs771681406 GRCh37 Chromosome 11, 32456526: 32456526
36 WT1 NM_024426.4(WT1): c.198G> T (p.Pro66=) single nucleotide variant Benign rs2234582 GRCh37 Chromosome 11, 32456694: 32456694
37 WT1 NM_024426.4(WT1): c.198G> T (p.Pro66=) single nucleotide variant Benign rs2234582 GRCh38 Chromosome 11, 32435148: 32435148
38 WT1 NM_024426.4(WT1): c.*1132A> T single nucleotide variant Likely benign rs5030328 GRCh38 Chromosome 11, 32387926: 32387926
39 WT1 NM_024426.4(WT1): c.*1132A> T single nucleotide variant Likely benign rs5030328 GRCh37 Chromosome 11, 32409472: 32409472
40 WT1 NM_024426.4(WT1): c.*1098C> T single nucleotide variant Likely benign rs5030327 GRCh38 Chromosome 11, 32387960: 32387960
41 WT1 NM_024426.4(WT1): c.*1098C> T single nucleotide variant Likely benign rs5030327 GRCh37 Chromosome 11, 32409506: 32409506
42 WT1 NM_024426.4(WT1): c.*1058G> T single nucleotide variant Uncertain significance rs886048211 GRCh37 Chromosome 11, 32409546: 32409546
43 WT1 NM_024426.4(WT1): c.*1058G> T single nucleotide variant Uncertain significance rs886048211 GRCh38 Chromosome 11, 32388000: 32388000
44 WT1 NM_024426.4(WT1): c.*1053_*1054dupGT duplication Uncertain significance rs878917290 GRCh37 Chromosome 11, 32409550: 32409551
45 WT1 NM_024426.4(WT1): c.*1053_*1054dupGT duplication Uncertain significance rs878917290 GRCh38 Chromosome 11, 32388004: 32388005
46 WT1 NM_024426.4(WT1): c.*897G> C single nucleotide variant Likely benign rs5030324 GRCh37 Chromosome 11, 32409707: 32409707
47 WT1 NM_024426.4(WT1): c.*897G> C single nucleotide variant Likely benign rs5030324 GRCh38 Chromosome 11, 32388161: 32388161
48 WT1 NM_024426.4(WT1): c.*864T> A single nucleotide variant Likely benign rs5030323 GRCh37 Chromosome 11, 32409740: 32409740
49 WT1 NM_024426.4(WT1): c.*864T> A single nucleotide variant Likely benign rs5030323 GRCh38 Chromosome 11, 32388194: 32388194
50 WT1 NM_024426.4(WT1): c.*835A> G single nucleotide variant Likely benign rs5030322 GRCh37 Chromosome 11, 32409769: 32409769

Expression for Wilms Tumor 5

Search GEO for disease gene expression data for Wilms Tumor 5.

Pathways for Wilms Tumor 5

Pathways related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.86 CTNNB1 FZD6 GPC3 IGF2
2 11.72 CTGF CTNNB1 FZD6 PAX2
3 11.59 CTNNB1 FZD6 IGF2
4 11.35 CTGF CTNNB1 CYR61 NOV
5 10.89 CDKN1C CTNNB1 PAX2 SYNPO WT1
6 10.53 PAX2 PAX8

GO Terms for Wilms Tumor 5

Biological processes related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.98 CTGF CYR61 NOV WISP3
2 regulation of gene expression GO:0010468 9.96 CTNNB1 IGF2 NOV PAX6
3 lung development GO:0030324 9.84 CTGF CTNNB1 GPC3
4 kidney development GO:0001822 9.83 CTNNB1 GPC3 PAX8 WT1
5 inner ear morphogenesis GO:0042472 9.82 FZD6 PAX2 PAX8
6 camera-type eye development GO:0043010 9.8 PAX2 PAX6 WT1
7 negative regulation of epithelial cell proliferation GO:0050680 9.8 CDKN1C GPC3 PAX6
8 transcription by RNA polymerase II GO:0006366 9.8 CTNNB1 PAX2 PAX6 PAX8 POU6F2 PRDM2
9 reactive oxygen species metabolic process GO:0072593 9.72 CTGF CYR61 PAX2
10 positive regulation of neuroblast proliferation GO:0002052 9.68 CTNNB1 PAX6
11 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.68 PAX2 PAX8
12 male genitalia development GO:0030539 9.67 CTNNB1 WT1
13 anterior/posterior axis specification GO:0009948 9.67 CTNNB1 GPC3
14 regulation of cell growth GO:0001558 9.67 CTGF CYR61 NOV WISP3
15 urogenital system development GO:0001655 9.66 PAX2 PAX8
16 mesonephros development GO:0001823 9.66 PAX2 PAX8
17 mesenchymal to epithelial transition GO:0060231 9.65 PAX2 WT1
18 cellular response to gonadotropin stimulus GO:0071371 9.64 PAX8 WT1
19 metanephric mesenchyme development GO:0072075 9.64 PAX2 WT1
20 dorsal/ventral axis specification GO:0009950 9.63 CTNNB1 PAX6
21 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.62 PAX2 PAX8
22 pronephros development GO:0048793 9.61 PAX2 PAX8
23 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.61 PAX2 PAX8
24 metanephric S-shaped body morphogenesis GO:0072284 9.6 PAX8 WT1
25 positive regulation of epithelial cell differentiation GO:0030858 9.59 CTNNB1 PAX6
26 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.58 PAX2 PAX8
27 metanephric nephron tubule formation GO:0072289 9.57 PAX2 PAX8
28 metanephric distal convoluted tubule development GO:0072221 9.56 PAX2 PAX8
29 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.54 PAX2 PAX8
30 pronephric field specification GO:0039003 9.51 PAX2 PAX8
31 cell fate determination GO:0001709 9.5 CTNNB1 PAX2 PAX6
32 positive regulation of metanephric DCT cell differentiation GO:2000594 9.49 PAX2 PAX8
33 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.48 PAX2 PAX8
34 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.46 PAX2 PAX8
35 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.43 PAX2 PAX8
36 negative regulation of cell death GO:0060548 9.35 CTGF CTNNB1 CYR61 NOV WISP3
37 metanephric epithelium development GO:0072207 9.33 PAX2 PAX8 WT1
38 branching involved in ureteric bud morphogenesis GO:0001658 9.02 CTNNB1 GPC3 PAX2 PAX8 WT1
39 cell adhesion GO:0007155 10.08 CTGF CTNNB1 CYR61 NOV WISP3
40 positive regulation of transcription, DNA-templated GO:0045893 10.06 CDKN1C CTNNB1 PAX2 PAX6 PAX8 WT1
41 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 CTNNB1 CYR61 IGF2 PAX2 PAX6 PAX8

Molecular functions related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.62 PAX2 PAX6 PAX8 WT1
2 growth factor activity GO:0008083 9.56 CTGF IGF2 NOV WISP3
3 heparin binding GO:0008201 9.46 CTGF CYR61 NOV WISP3
4 integrin binding GO:0005178 9.35 CTGF CYR61 IGF2 NOV WISP3
5 insulin-like growth factor binding GO:0005520 8.92 CTGF CYR61 NOV WISP3

Sources for Wilms Tumor 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....